The Future Ai

The researchers found that the GLP‑1 receptor agonists reduced the risk of major adverse cardiovascular events, such as heart attack, stroke, and cardiovascular death, by approximately 13% compared with placebo over an average follow‑up of almost three years.Why are the new findings significant?These new findings are significant because they focus on the long-term benefits of the drug; Only studies with a minimum one-year follow-up were considered. The results are also independent of whether or not a patient is diabetic.The researchers also found that people who took the drugs were less likely to die from any cause, and experienced lower rates of non‑fatal heart attacks, non‑fatal strokes, and hospital admissions for heart failure.The benefits were seen in people at increased cardiovascular risk, including those with type 2 diabetes, obesity, or existing heart disease.The review found no major increase in serious safety risks, such as severe hypoglycaemia or acute pancreatitis, compared with placebo. There were some gastrointestinal side effects, such as nausea and vomiting, which were more common but are already well recognized.What are the experts saying?GLP‑1 receptor agonists, including medications such as semaglutide, liraglutide, and dulaglutide, are gaining popularity recently for their effectiveness in treating obesity.“This is the most comprehensive review to date of long‑term cardiovascular outcome trials for GLP‑1 receptor agonists. We know that one of the factors that weighs on people’s minds when considering going onto these drugs is the potential long-term side effects,” lead author Dr Simon Cork, Physiology lead at Anglia Ruskin University’s School of Medicine, said, in a release.“Our results show that, when taken over a prolonged period of at least one year, these medications do much more than help control blood sugar or weight. They significantly reduce the risk of heart attacks, strokes, and premature death in people who are already vulnerable. We found the benefits to be consistent across different drugs, trial designs, and patient groups. This has important implications for clinical practice and health policy, particularly given that cardiovascular disease is the leading cause of death in the UK,” Dr Cork added.“These drugs have the potential to become a key part of healthcare strategies, especially for people with type 2 diabetes or established heart disease. Using them earlier and more widely across populations could help prevent thousands of serious cardiovascular events,” he concluded.